Global Biosimilar Monoclonal Antibodies Market Expected to Reach US$ 9240 million by 2024 | Celltrion, Pfizer, 3SBIO, Novartis, Dr Reddy's, Celgen Biopharma, Cadila Healthcare, Hisun Pharma

Biosimilar Monoclonal Antibodies market will register a 27.5% CAGR in terms of revenue, the global market size will reach US$ 9240 million by 2024, from US$ 2750 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biosimilar Monoclonal Antibodies business.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.

Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.

Get More Information Download Sample Copy at https://www.reportsweb.com/inquiry&RW00012598823/sample

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.

The key manufacturers covered in this report:
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy's
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.

This study considers the Biosimilar Monoclonal Antibodies value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other

Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Oncology
Autoimmune Disease
Other

Inquire for Report at https://www.reportsweb.com/inquiry&RW00012598823/buying

Table of Contents:

2019-2024 Global Biosimilar Monoclonal Antibodies Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
3 Global Biosimilar Monoclonal Antibodies by Players
4 Biosimilar Monoclonal Antibodies by Regions
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Marketing, Distributors and Customer
11 Global Biosimilar Monoclonal Antibodies Market Forecast
12 Key Players Analysis
13 Research Findings and Conclusion

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Pune, India

This release was published on openPR.